RPE65 Transgene Optimization for Sustained Ocular Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapies for Leber congenital amaurosis 2 (LCA2) using adeno-associated virus (AAV) vectors face challenges in long-term efficacy and transgene expression, necessitating strategies to enhance gene transfer potential and protein expression.
Innovation Solution
Development of codon-optimized and Kozak sequence-containing RPE65 vectors for ocular gene therapy, utilizing AAV packaging cell lines, transfection, cell lysis, and purification processes to produce optimized transgenes with sequences pAAV.CMV.CodOpt.RPE65 and pAAV.CMV.Kozak.RPE65.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional AAV2 vectors are used for gene therapy in LCA2, then initial therapeutic response is achieved, but long-term efficacy and sustained transgene expression are insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the viral capsid through capsid engineering at specific sites (SUMOylation, neddylation, phosphorylation, and ubiquitination sites) to alter vector properties. This enhances the vector's ability to achieve long-term gene transfer potential and sustained transgene expression in the ocular niche, directly resolving the contradiction between initial therapeutic response and long-term efficacy.
Solution Approach 2:
The patent employs composite materials by combining capsid engineering with codon optimization of the transgene. This composite approach integrates multiple modification strategies (capsid mutations plus transgene optimization) to achieve enhanced and sustained RPE65 protein expression, thereby improving long-term therapeutic reliability.
2Quantity of substance
If standard transgene sequences are used, then gene transfer is achieved, but transgene expression level is insufficient
Solution Approach 1:
The patent applies parameter changes by implementing codon optimization of the RPE65 transgene sequence. This optimization adjusts codon usage to match the preferred codons of the host organism, thereby enhancing translation efficiency and protein formation. The optimized transgene sequences (pAAV.CMV.CodOpt.RPE65 and pAAV.CMV.Kozak.RPE65) result in significantly higher RPE65 protein expression levels.
Solution Approach 2:
The patent employs preliminary action by pre-optimizing the transgene sequence before integration into the AAV vector. The codon optimization and Kozak sequence addition are performed in advance during transgene construction, ensuring that when the vector is delivered to the host, the transgene is immediately expressed at high levels without requiring additional modification steps.
3Reliability
If capsid engineering is performed to enhance vector efficacy, then gene transfer potential is improved, but vector design complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the vector modification strategy into distinct, manageable components: capsid engineering at specific sites (SUMOylation, neddylation, phosphorylation, ubiquitination) and separate transgene optimization. This segmentation allows each component to be optimized independently while working together to enhance overall gene transfer potential, making the complex vector design more systematic and reproducible.
Data Source
AI summary
A system for an ocular gene therapy is provided. The system includes one or more optimized transgenes. The one or more optimized transgenes include pAAV.CMV.CodOpt.RPE65 and pAAV.CMV.Kozak.RPE65. The optimized transgenes pAAV.CMV.CodOpt.RPE65 and pAAV.CMV.Kozak.RPE65 have shown to exhibit enhanced RPE65 gene expression when compared to wild type RPE65 gene transfer in suitable models. These optimized genes may enhance therapeutic response during LCA2 gene therapy. The present invention also provides a process for preparing the optimized transgene for an ocular gene therapy.